Cormorant Asset Management »

Immunitybio shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Immunitybio (IBRX) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Immunitybio

Tip: Access up to 7 years of quarterly data

All positions including Immunitybio held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Immunitybio by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $7.9M 1.3M 6.32

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Arcellx Common Stock (ACLX)
Vaxcyte (PCVX)
Longboard Pharmaceuticals In (LBPH)
Eyepoint Pharmaceuticals Com New (EYPT)
Rapport Therapeutics (RAPP)
Crinetics Pharmaceuticals In (CRNX)
Edgewise Therapeutics (EWTX)
Merus N V (MRUS)
Bridgebio Pharma (BBIO)
Insmed Com Par $.01 (INSM)
Newamsterdam Pharma Company Ordinary Shares (NAMS)
Janux Therapeutics (JANX)
Axsome Therapeutics (AXSM)

View all positions for Cormorant Asset Management

Top funds holding Immunitybio

Vanguard Group
BlackRock
BlackRock
State Street Corporation
Geode Capital Management
Bank of America Corporation
Susquehanna International
Charles Schwab Investment Management
Cormorant Asset Management
Northern Trust
Jpmorgan Chase & Co
Goldman Sachs Group
Citadel Advisors
Jane Street
First Trust Advisors

View all funds holding Immunitybio